Bausch Health Co. Inc. (BHC) Q3 Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Bausch Health Co. Inc. (BHC) Reports U.S. Launch of BRYHALI (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis in Adults
November 7, 2018 7:23 AM ESTBausch Health Companies Inc. (NYSE: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced it expects to start distribution of BRYHALI (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for BRYHALI Lotion on Nov. 6, 2018. BRYHALI Lotion, which is indicated for the topical treatment of plaque psoriasis in adult patients, is a new potent to superpotent corticosteroid in a novel vehicle lotion with safety established for... More
Bausch Health Companies (BHC) PT Raised to $31 at RBC Capital
November 7, 2018 7:10 AM ESTRBC Capital analyst Doug Miehm raised the price target on Bausch Health Companies (NYSE: BHC) to $31.00 (from $30.00) while maintaining a Sector Perform rating.
... More